MarketMoodz
Skyrizi 55% Crohn’s remission boosts AbbVie vs J&J
AbbVie says AFFIRM topline data show Skyrizi reached clinical remission at week 12 in 55% of Crohn’s disease patients versus 30% on placebo, strengthening its competitive position against Johnson & Johnson’s Tremfya. Endoscopic response also led at 44% versus 14% for placebo, though primary topline definitions require confirmation from the AFFIRM dataset.
Key Takeaways
- AFFIRM topline shows 55% clinical remission at week 12 vs 30% placebo.
- Endoscopic response at week 12: 44% for Skyrizi vs 14% for placebo.
- Trial population skewed toward treatment-refractory patients (65% failed 2+ advanced therapies).
- Tremfya remains a close competitor; dosing/regimen differences influence market share.
- AbbVie cites roughly 75% in-play capture rate for frontline IBD; fully subcutaneous induction could narrow convenience gap.
People Involved
- AbbVie Management Executive leadership of AbbVie
- William Blair Analyst
- Barclays Analyst
- RBC Capital Markets Analyst
- Piper Sandler Analyst
Entities Involved
- AbbVie Inc. (ABBV) Biopharmaceutical company developing Skyrizi
- Johnson & Johnson Parent company of Tremfya; major competitor
- Tremfya IL-23 inhibitor competing with Skyrizi
MarketMoodz Analysis
The topline AFFIRM data, if validated against the primary topline release, position Skyrizi as a stronger option for frontline Crohn’s disease patients, potentially shifting payer negotiations and early-adoption dynamics in AbbVie’s favor. The emphasis on remission at 12 weeks and robust endoscopic response undercuts the advantage Tremfya claims on convenience in the IL-23 class, even as real-world adherence and access remain pivotal for market share.
Historically, IL-23 inhibitors have gained momentum against anti-TNFs in Crohn’s, but patient access hinges on dosing convenience and payer coverage. If AFFIRM results sustain, AbbVie could push for a more patient-friendly induction strategy (fully subcutaneous) to close the gap with Tremfya; investors should watch AFFIRM primary topline verification, regulatory updates, and payer-negotiation signals in the coming quarters.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial